CASE STUDY | PHARMACEUTICAL MARKET ACCESS
When Access Was Complex, We Aligned the System.
THE CHALLENGE
Expanding Into Biosciences with Limited Established Presence
A biopharma company known for generics and hospital IV products expanded into biosciences with the rapid launch of biosimilars and oncology injectables.
The organization needed to establish credibility as a biosciences manufacturer while building relationships with key decision-makers, including health system and community oncology pharmacy directors.
At the same time, success depended on driving uptake in a complex access environment, supporting payer acceptance while maintaining provider value and enabling pull-through in settings with limited coverage.
THE BREAKTHROUGH
Aligning Value, Stakeholders, and Execution to Support Uptake
BGBx identified that success required more than awareness. It required ensuring value communication reflected how access decisions are made in oncology.
Using our Breakthrough Process, powered by 3D Science, we tested strategy against payer, provider, and institutional dynamics to confirm value positioning would hold under real-world decision criteria.
The approach integrated:
- Development of a unified biosciences brand identity to establish credibility
- Stakeholder-specific communication to raise awareness of the expanding portfolio
- Targeted engagement with institutional pharmacy directors and oncology practices
- Buy-and-bill strategy aligned to reimbursement dynamics, enabling provider adoption
- Field activation to reinforce positioning and support uptake across accounts
THE RESULTS
Transforming Access Strategy Into Measurable Portfolio Growth
The biosimilar portfolio became the company’s fastest-growing product segment, driving revenue growth through deep expertise in buy-and-bill reimbursement dynamics and alignment of messaging to the priorities of key organizational stakeholders.
94%
Portfolio Revenue Increase
Between 2019 and 2025
Our Perspectives on Advertising
2026 Oncology Market Access Trends
Implications of the IRA’s Maximum Fair Price (MFP) Negotiations
340B Drug Discount Program
Let’s Plan Your Next Market Access Breakthrough
At BGBx, we turn access strategy into execution. We align value, stakeholders, and delivery systems to support uptake and strengthen performance in complex market environments.
